Member Comments are provided by individuals and reflect their personal opinions only. Under NO circumstances should you act on any advice or opinion posted in this forum. ALWAYS check with your personal physician before taking any action regarding your health! MedHelp International and our partners, sponsors and affiliates have no obligation to monitor any comments posted on this site, or the content and/or accuracy of such exchanges. MedHelp International does not endorse the views of any user.
Overusage of antidepressants
by xanweaner, Mar 02, 2008 10:12PM
I was wondering if anyone reading this has wondered if antidepressants are overused. I just found this amazing article by Dr. Loren Mosher, a reknowned psychiatrist with credentials from both Stanford and Harvard, and thought our readers would be interested. I found his article compelling.
How Drug Company Money Has Corrupted Psychiatry
by Loren R. Mosher, M.D.
The American Psychiatric Association (APA) is the nationwide organization to which most psychiatrists belong. In some ways it is a trade union. A large proportion of its income is from drug company advertising in its journals and newspaper. It also receives "unrestricted educational grants" and convention revenue from drug companies. Drug company sponsored symposia and exhibitions dominate the two major annual psychiatric conventions. Of course, the symposia speakers are paid handsomely for their half-day appearances. In my opinion, the APA is so dependent on pharmaceutical company support that it can not afford to criticize the overuse and misuse of psychotropic drugs. Perhaps more importantly, the APA is unwilling to mandate education of psychiatrists about the the seriousness of the short and long-term toxicities and withdrawal reactions from the drugs.
The drug companies pay speakers ($1000-2000 per appearance) who give psychiatric grand rounds and/or evening speeches (dinner provided by the company) to local psychiatric societies. Speakers come from lists of psychiatrists who will basically endorse their products. Doctors training to be psychiatrists are specially targeted for these speakers.
The drug companies give contracts to university based and private psychiatric research companies to conduct drug trials that are required for U.S. Food & Drug Administration (FDA) approval of the drugs they sell. The company provides the protocol and the researcher may receive as much as $40,000 per patient that completes the study. This allows the drug company considerable influence on the way the drug studies are conducted. All of these drug manufacturer activities have increased in scope and intensity since the introduction of newly patented drugs, beginning with Prozac in 1989. They must reap the profits before patents run out.
Research protocols used in studies of psychiatric drugs required for the approval of the FDA are supposed to be reviewed by Institutional Review Boards (IRB's) to be sure they do not pose undue risks to the study subjects. Members of these boards have been found to be highly paid consultants to drug companies whose protocols they review. That is, they have obvious conflicts of interests and are not objective, unbiased reviewers of the psychiatric drug studies over which they pass judgment. The latest "novel" anti-psychotic drug that has been approved by our federal drug regulatory agency (FDA) is Zeldox, which the FDA allowed to be introduced to the US market despite Zeldox's dangers.
In my view American psychiatry has become drug dependent (that is, devoted to pill pushing) at all levels - private practitioners, public system psychiatrists, university faculty and organizationally. What should be the most humanistic medical specialty has become mechanistic, reductionistic, tunnel-visioned and dehumanizing. Modern psychiatry has forgotten the Hippocratic principle: Above all, do no harm.
THE AUTHOR, Loren R. Mosher, holds a B.A. from Stanford University and an M.D., with honors, from Harvard Medical School, where he subsequently received his psychiatric training. He is now Clinical Professor of Psychiatry, School of Medicine, University of California, San Diego, and Director of Soteria Associates, 2616 Angell Avenue, San Diego, Calif. 92122, (858) 550-0312, Fax (858) 558-0854. See www.mosher-soteria.com.
How Drug Company Money Has Corrupted Psychiatry
by Loren R. Mosher, M.D.
The American Psychiatric Association (APA) is the nationwide organization to which most psychiatrists belong. In some ways it is a trade union. A large proportion of its income is from drug company advertising in its journals and newspaper. It also receives "unrestricted educational grants" and convention revenue from drug companies. Drug company sponsored symposia and exhibitions dominate the two major annual psychiatric conventions. Of course, the symposia speakers are paid handsomely for their half-day appearances. In my opinion, the APA is so dependent on pharmaceutical company support that it can not afford to criticize the overuse and misuse of psychotropic drugs. Perhaps more importantly, the APA is unwilling to mandate education of psychiatrists about the the seriousness of the short and long-term toxicities and withdrawal reactions from the drugs.
The drug companies pay speakers ($1000-2000 per appearance) who give psychiatric grand rounds and/or evening speeches (dinner provided by the company) to local psychiatric societies. Speakers come from lists of psychiatrists who will basically endorse their products. Doctors training to be psychiatrists are specially targeted for these speakers.
The drug companies give contracts to university based and private psychiatric research companies to conduct drug trials that are required for U.S. Food & Drug Administration (FDA) approval of the drugs they sell. The company provides the protocol and the researcher may receive as much as $40,000 per patient that completes the study. This allows the drug company considerable influence on the way the drug studies are conducted. All of these drug manufacturer activities have increased in scope and intensity since the introduction of newly patented drugs, beginning with Prozac in 1989. They must reap the profits before patents run out.
Research protocols used in studies of psychiatric drugs required for the approval of the FDA are supposed to be reviewed by Institutional Review Boards (IRB's) to be sure they do not pose undue risks to the study subjects. Members of these boards have been found to be highly paid consultants to drug companies whose protocols they review. That is, they have obvious conflicts of interests and are not objective, unbiased reviewers of the psychiatric drug studies over which they pass judgment. The latest "novel" anti-psychotic drug that has been approved by our federal drug regulatory agency (FDA) is Zeldox, which the FDA allowed to be introduced to the US market despite Zeldox's dangers.
In my view American psychiatry has become drug dependent (that is, devoted to pill pushing) at all levels - private practitioners, public system psychiatrists, university faculty and organizationally. What should be the most humanistic medical specialty has become mechanistic, reductionistic, tunnel-visioned and dehumanizing. Modern psychiatry has forgotten the Hippocratic principle: Above all, do no harm.
THE AUTHOR, Loren R. Mosher, holds a B.A. from Stanford University and an M.D., with honors, from Harvard Medical School, where he subsequently received his psychiatric training. He is now Clinical Professor of Psychiatry, School of Medicine, University of California, San Diego, and Director of Soteria Associates, 2616 Angell Avenue, San Diego, Calif. 92122, (858) 550-0312, Fax (858) 558-0854. See www.mosher-soteria.com.
Related discussions
-
What to do when another pannic attack occurs (20 replies):I experienced my first panic attack last week and I am s...[more]
-
is zoloft keeping me anxious? (21 replies):I am a thirty-eight year old woman whose been surviving ...[more]
-
SSRIs Side Effects and Withdrawal Symptoms (19 replies):They exist. They matter. They have ruined and, in some...[more]
-
LEXAPRO. need advice! (15 replies):I was recently diagnosed with depression and prescribed ...[more]
Post Comment
Related Communities
Recent Videos
Related Expert Forums
Recent Activity
Most Popular Trackers
RSS
Expert Activity
Community Members
I completely agree with you. I just posted on Dr. Choi's comments on the recent study about the limited effectiveness of SSRI's on treating mild to moderate depression. Check out the posts.
What frightens me even more is that the Internal Medicine docs and family practioners are also prescribing antipsychotic drugs, like Zyprexa to their patients. With the potential for severe adverse events, they are not the specialities to be prescribing these meds.
It's a shame that a Dr. as outspoken as Dr. Mosher had to pass away. I wonder who will fill his shoes to advocate for patient safety and educating the public about the dangers of indiscriminate antidepressant and psycotropic medications prescribing.